Author:
Toyoshima Shigeki,Kanno Akihiro,Kitayama Tetsuya,Sekiya Koji,Nakai Keiko,Haruna Masao,Mino Terumasa,Miyazaki Hiroyasu,Yano Koji,Yamamoto Keiji
Publisher
Japanese Pharmacological Society
Subject
Pharmacology,Molecular Medicine
Reference49 articles.
1. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology
2. 2 ICH Harmonised Tripartite Guideline, The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals S7B. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; http://www.ich.org/.
3. 3 ICH Harmonised Tripartite Guideline, Safety Pharmacology Studies for Human Pharmaceuticals S7A. Recommended for adoption at step 4 of the ICH process on 8 November 2000 by the ICH Steering Committee. ICH; http://www.ich.org/.
4. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey
5. 5 Goldberg MR, Porras AG, Greber TF, Somers G, Pruitt L, Desmet M. MK-499 plasma concentrations (PC) and sustained effects of QTc interval in healthy volunteers (HV). Clin Pharmacol Ther. 1994;55:158.
Cited by
85 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献